Original Research Article

Efficient genome editing in *Claviceps purpurea* using a CRISPR/Cas9 ribonucleoprotein method

Lu Yu, Meili Xiao, Zhihua Zhu, Yinmei Wang, Zhihua Zhou, Pingping Wang, Gen Zou

** Corresponding author. CAS-Key Laboratory of Synthetic Biology, CAS Center for Excellence in Molecular Plant Sciences, Institute of Plant Physiology and Ecology, Chinese Academy of Sciences, 300 Fenglin Rd, Shanghai, 200032, China.
** Corresponding author. CAS-Key Laboratory of Synthetic Biology, CAS Center for Excellence in Molecular Plant Sciences, Institute of Plant Physiology and Ecology, Chinese Academy of Sciences, 300 Fenglin Rd, Shanghai, 200032, China.
E-mail addresses: yulu31081@126.com (L. Yu), xiaomeili@sippe.ac.cn (M. Xiao), zhuzhu2016@ecmps.ac.cn (Z. Zhu), wangyinmei@ecmps.ac.cn (Y. Wang), zhoushuibu@sippe.ac.cn (Z. Zhou), pwwang@ecmps.ac.cn (P. Wang), zougen@sibs.ac.cn (G. Zou).

** These authors contributed equally to this work.

** Peer review under responsibility of KeAi Communications Co., Ltd.

** Available online 16 February 2022

** 2405-805X/© 2022 The Authors. Publishing services by Elsevier B.V. on behalf of KeAi Communications Co. Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/)

ABSTRACT

*Claviceps purpurea* produces many pharmacologically important ergot alkaloids (EAS), which are widely used to treat migraine and hypertension and to aid childbirth. Although an EAS biosynthetic cluster of *C. purpurea* has been discovered more than 20 years ago, the complete biosynthetic pathway of EAS has not been fully characterized until now. The main obstacle to elucidating this pathway and strain modification is the lack of efficient genome-editing tools for *C. purpurea*. The conventional gene manipulation method for *C. purpurea* relies on homologous recombination (HR), although the efficiency of HR in *C. purpurea* is very low (−1–5%). Consequently, the disruption of target genes is laborious and time-consuming. Although CRISPR/Cas9 genome-editing methods based on in vivo Cas9 expression and gRNA transcription have been reported recently, their gene disruption efficiency is still very low. Here, we developed an efficient genome-editing system in *C. purpurea* based on in vitro assembled CRISPR/Cas9 gRNA ribonucleoprotein complexes. As proof of principle, three target genes were efficiently knocked out using this CRISPR/Cas9 ribonucleoprotein complex-mediated HR system, with editing efficiencies ranging from 50% to 100%. Inactivation of the three genes, which are closely related to uridine biosynthesis (*ura5*), hypha morphology (*rac*), and EAS production (*easA*), resulted in a uridine auxotrophic mutant, a mutant with a drastically different phenotype in axenic culture, and a mutant that did not produce EAS, respectively. Our ribonucleoprotein-based genome-editing system has a great advantage over conventional and in vivo CRISPR/Cas9 methods for genome editing in *C. purpurea*, which will greatly facilitate elucidation of the EAS biosynthetic pathway and other future basic and applied research on *C. purpurea*.

1. Introduction

*Claviceps purpurea* is a phytopathogenic fungus that grows on cereals and forage grasses. It produces pharmacologically important ergot alkaloids (EAS), such as ergosine, ergocristine, ergotamine, and ergonovine, which have been used to treat migraine, hypertension, or to aid childbirth [1]. An EAS biosynthetic cluster of *C. purpurea* was first discovered in 1999 [2], and several genes in the cluster have been characterized functionally by gene disruption and analysis of the intermediates [3–7]. However, the P450 enzyme responsible for the formation of key precursor elymoclavine and the non-ribosomal peptide synthases (NRPS) for the biosyntheses of downstream ergosine and ergocristine remained elusive [5]. Candidate genes for the above miss enzymes have been proposed either within or beyond the EAS cluster,
efficient gene disruption tools would largely benefit the characterization and validation of these candidates.

The conventional gene-manipulation method in *C. purpurea* incorporates selection markers into the genome via homologous recombination (HR); however, the efficiency of HR in *C. purpurea* is very low (1–5%) [5,8]. The disruption of target genes is expensive and time-consuming. Therefore, it is necessary to develop an efficient, versatile genome editing tool. This system consists of a Cas9 nuclease and a functional guide RNA (gRNA) [15]. The gRNA recognizes the target sequence in the genome, and the Cas9 nuclease cleaves the sequence to generate double-strand DNA breaks (DSBs) [16]. Then, the cells repair these breaks via nonhomologous end-joining or HR using exogenous DNA (donor DNA), resulting in insertion or deletion mutagenesis at targeted genomic loci [17,18]. CRISPR/Cas9 systems can be established by either in vivo or in vitro strategies. In the in vivo strategy, cassettes expressing Cas9 and gRNA with appropriate promoters are introduced into cells to produce a functional Cas9/gRNA complex in vivo [19]. Recently, an approach for CRISPR/Cas9-mediated mutagenesis in *C. purpurea* using in vivo expression of Cas9 and gRNA was described [20]. However, this strategy does not work well, since the editing efficiency of CRISPR/Cas9-mediated homology-directed repair was only slightly better than HR-mediated knock-out of the *TrpE* gene (4/116 and 6/384, respectively). In the in vitro strategy, the purified Cas9 protein and in vitro transcript gRNA are assembled in vitro to generate a functional Cas9/gRNA ribonucleoprotein (RNP) and then transformed into cells for genome editing. This strategy has obvious advantages over the in vivo strategy, as assembly of the Cas9/gRNA complex is not limited by the amount or rate of Cas9 translation or gRNA transcription in vivo. The editing efficiency reached 100% in the filamentous fungi *Trichoderma reesei* [11,21,22] and *Cordyceps militaris* [23,24] after optimizing the RNP-based method.

Here, we developed an efficient CRISPR/Cas9-mediated genome-editing method for *C. purpurea* using the in vitro strategy. Three target genes, which are closely related to uridine biosynthesis (*ura5*, encoding orotate phosphoribosyl transferase catalyzing the transformation of orotate to OMP in the pyrimidine pathway; accession No. KAG6317199) [25], hypha morphology (*rac*, encoding small GTPase involved in polarity, sporulation and hyphal growth of *C. purpurea*; accession No. CAOB2105) [26], and EAS production (*eaA*, encoding chanoclavine-I aldehyde oxidoreductase catalyzing chanoclavine-I-aldehyde to form more-complex ergot alkaloids; accession No. Q6ZXC1) [27], were selected to verify the efficiency of this system. In the experiments, all three genes were efficiently knocked out by the CRISPR/Cas9-mediated HR.

2. Materials and methods

2.1. Strains and culture media

The strain *C. purpurea* 3.1003 was purchased from China General Microbiological Culture Collection Center (CGMCC, Beijing, China), which was grown on potato dextrose agar medium (200 g potato infusion, 20 g dextrose, 20 g agar to 1 L water). For the fermentation of *C. purpurea* strain, the mycelia were cultivated for 5 days in the seed medium TS (100 g/L sucrose, 10 g/L asparagine, 0.5 g/L KH₂PO₄, 0.25 g/L MgSO₄·7H₂O, 0.007 g/L FeSO₄·7H₂O, 0.006 g/L ZnSO₄·7H₂O, 0.12 g/L KCl, at pH 5.2) and cultivated in the dark at 24 °C on a rotary shaker (200 rpm) for 4 weeks. *C. purpurea* was grown at 28 °C either for 3 days in CD medium [11] for protoplast preparation, or for 2 days in SDB medium (40 g/L dextrose, 10 g/L yeast extract, 10 g/L tryptone) for genomic DNA isolation. Protoplast regeneration medium was used as described by Zou et al. [2020] [11]. *Escherichia coli* Top10 used for gene cloning was cultured at 37 °C in Luria Bertani (LB) medium with ampicillin (100 μg/mL). Primers used in this study are listed in Table S2.

2.2. Preparation of target gene, Cas9 protein and gRNAs

Cas9 protein tagged with a nuclear localization signal was purchased from Novoprotein, Inc. (Shanghai, China). Since the genomic information of *C. purpurea* 3.1003 has not been reported yet, primers were designed to amplify the target genes using *C. purpurea* 20.1 as a reference. In vitro transcription of gRNA was carried out as previously described by Zou et al. [11]. The in vitro RNA product was incubated with Cas9 at 37 °C for 15 min to form a Cas9-gRNA complex before transformation into protoplasts. The assembling reaction system contained 6 μL Cas9 (1 μg/μL), 30 μL 10 × Cas9 activity buffer (0.2 M HEPES, 1.5 M KCl, 5.0 mM dithiothreitol, 1.0 mM EDTA, 0.1 M MgCl₂, pH 7.5), 5 μL gRNA (~3 μg/μL) and 46 μL 2 × S2 solution (2 M sorbitol, 100 mM CaCl₂, 20 mM Tris-HCl, pH 7.5).

2.3. Protoplast preparation, transformation and selection

Mature conidia of *C. purpurea* were collected with 0.85% NaCl-0.02% Tween 80 and inoculated in 100 mL CD liquid medium for 3 days at 28 °C. The mycelia were then collected by filtration, and washed with solution 1 (1.2 M sorbitol, 0.1 M KH₂PO₄, pH 5.5). After that, the mycelia were suspended in 20 mL solution 1 with 12.5 mg/L lysing enzymes from *Trichoderma harzianum* (Sigma-Aldrich, St. Louis, MO, USA) and incubated at 28 °C for 2 h by mild agitation (50 rpm). The protoplasts were then separated from mycelia by filtration through sterilized Miracloth (Sigma-Aldrich). Then they were gently precipitated by centrifugation (2000 × g, 10 min, 4 °C) and washed once again with 4 mL solution 2 (1 M sorbitol, 50 mM CaCl₂, 10 mM Tris-HCl, pH 7.5). Finally, the protoplasts were resuspended in solution 2 to a concentration of 10⁶/mL for subsequent transformation. Protoplasts release was checked by microscopic observation. The Cas9-gRNA complex and donor DNA were added into 200 μL of the above protoplast suspension. The aliquot was incubated on ice for 20 min and then solution 3 (2 mL) was added to the aliquot. After 30 min of incubation at 25 °C, solution 2 (4 mL) was added to the mixture. The resulting mixture was then poured into 50 mL melted regeneration medium containing 1.5 mg/mL hygromycin B and divided into three plates. After 7 days cultivation at 28 °C, transformants were inoculated onto a 24-well PDA plate (with 0.5 mg/mL hygromycin B). Colonies were picked and cultured in SDB for genomic DNA extraction. Gene disruption was validated by PCR amplification with primer pairs flanking the target site. All the sequence analyses of transformants were carried out by Sangon Biotech (Shanghai, China).

2.4. Construction of donor DNAs

The donor DNAs containing the 5’ and 3’ flanking sequences of target gene and the selectable marker cassette (Ptrpc-lph-Ttrpc) were generated by overlapping PCR using IS5 DNA polymerase (Tsingke, Beijing, China) and ligated into the pMD-18T vector (Takara, Tokyo, Japan). The generated vector was propagated in *E. coli* Top10 and purified using the Plasmid Midi Kit (Qiagen, Hilden, Germany).
2.5. Analysis of ergot alkaloids

For alkaloid extraction and determination, cultures were extracted twice with ethyl acetate, and concentrated for further alkaloid analysis by HPLC. An Agilent 1100 HPLC system with a 5 μm particle diameter, 250 × 4.6 mm) was used to separate and detect the alkaloids. The flow rate was 0.8 mL/min with a gradient elution of 15–95% (v/v) acetonitrile in 10 mM ammonium carbonate for 50 min. Detection was at 320 nm. Authentic ergocristine was purchased from Sigma–Aldrich Analyticals (Taufkirchen, Germany).

3. Results and discussion

3.1. Establishing genetic transformation and in vitro assembled Cas9/gRNA complex for C. purpurea

The PEG-mediated protoplast transformation method was used to establish the genetic transformation system (Fig. 1). C. purpurea protoplasts were collected based on the preparation method used in Aspergillus oryzae with some modifications [11]. As shown in Fig. S1, approximately 107 protoplasts/mL were obtained after incubating mycelia with 12.5 mg/mL lyzing enzyme for 2 h, which is sufficient for a transformation experiment. The efficiency of this genetic transformation system was confirmed by transferring the Ptpc-ble-TrpC fragment into the prepared protoplasts. After culturing at 28 °C for 7 days, monophyletic colonies were observed in the regeneration medium (containing phleomycin 30, 60, and 120 μg/mL) (Fig. S2), indicating that the Ptpc-ble-TrpC fragment was successfully inserted into the C. purpurea genome, as confirmed by diagnostic PCR (Fig. S3).

To identify a resistance marker for genetic manipulation, phleomycin was primarily used as a selection agent based on a previous study in C. purpurea [5,8]. The resistance of C. purpurea to phleomycin increased with the pH of the culture medium. On pH 6.0 plates, phleomycin at 40–200 μg/mL lacked toxic effects, while phleomycin had strong restraining effects on a pH 8.0 plate containing 40 μg/mL phleomycin (Fig. S4). However, a high pH was not beneficial for the regeneration of C. purpurea protoplasts. Therefore, hygromycin, which is commonly used for genetic manipulation of fungi, was tested. After culturing at 28 °C for 27 days, mycelia growth was completely inhibited at a minimum inhibitory concentration of 0.5 mg/mL hygromycin on PDA plates (pH 6.0), which was used in the subsequent experiments (Fig. S5).

To develop an in vitro strategy for efficient genome editing in C. purpurea based on CRISPR/Cas9 technology, gRNAs for the target genes were transcribed in vitro via runoff reactions using T7 RNA polymerase. To improve the editing efficiency, gRNAs were designed for each target gene. Then, the in vitro RNA products were incubated with Cas9 protein to generate Cas9/gRNA complexes, according to our previously established CRISPR/Cas9 genome editing approaches for several fungi [11]. Next, the complexes were transformed into C. purpurea via PEG-mediated protoplast transformation (Fig. 1).

3.2. Gene disruption using the RNP-based CRISPR/Cas9 system in C. purpurea

A previous study used an HR strategy for genome editing in C. purpurea. However, HR was inefficient (9 positive transformants of 181 selected) [5]. Here, we first tested the efficiency of the ribonucleoprotein-based CRISPR/Cas9 system to stimulate HR using exogenous DNA (donor DNA) in C. purpurea by targeting the ura5 gene encoding orotate phosphoribosyl transferase; this enzyme converts 5-fluoroorotic acid (5-FOA) into a toxic compound that severely inhibits the growth of wild fungal strains on medium. By contrast, the ura5 disruption mutant survives on plates with additional 5-FOA and uridine in the medium [11]. Three gRNAs were designed to target ura5 (Fig. 2a) and were then incubated with Cas9 protein to generate Cas9/gRNA complexes. After co-transformation of the Cas9/gRNA complexes and donor DNA (containing the hph expression cassette) into C. purpurea, 12 transformants were obtained by hygromycin screening. Successful disruption of the ura5 gene was indicated by a 4 kb PCR fragment produced using primers yUra5-F and yUra5-R and confirmed by sequencing the PCR product. Of the 12 colonies checked, 6 ones showed correct homologous integration (Fig. 2b), representing an editing efficiency of 50%. The PCR sequence from the remaining 6 obtained colonies demonstrated that the hygromycin selection marker was not incorporated into these colonies (Fig. 2c) as well as no mutations were found in all of the three targeted regions of their ura5 genes (Fig. S6). These results indicated that we obtained half true colonies with the expected homologous recombination and half false positive colonies. The phenotypic study showed that the ura5-disruption mutant cannot survive on CD plates without uridine (Fig. 2d). Moreover, the uridine

![Fig. 1. Overview of the RNP-based genome-editing system in C. purpurea in this study. Mature C. purpurea conidia were collected using 0.85% NaCl-0.02% Tween 80 and inoculated into 100 mL CD liquid medium. After 3 days, mycelia were collected and then suspended in solution 1 containing lyzing enzymes to prepare protoplasts. Protoplasts were resuspended in solution 2 to a concentration of 107/mL for subsequent transformation. RNA prepared in vitro was incubated with Cas9 at 37 °C for 15 min to form a Cas9/gRNA RNP complex. This complex was transformed into protoplasts with donor DNA. Finally, the resulting mixture was poured into 50 mL melted regeneration medium containing 1.5 mg/mL hygromycin B and divided into three plates.](image-url)
auxotrophic mutant could survive on PDA plates supplemented with 0.3 mg/mL 5-FOA and 10 mM uridine, while the wild-type showed no 5-FOA resistance (Fig. S7).

The ura5 gene has been used as an effective selection marker for genome editing in fungi [11, 28]. As there are few selection markers for genome editing in C. purpurea, the ura5 gene may serve as an additional selectable marker for genome engineering in C. purpurea.

We subsequently tested the efficiency of the ribonucleoprotein-based CRISPR/Cas9 system at stimulating HR in C. purpurea by targeting the rac gene, which strongly influences the morphology of C. purpurea hyphae [26]. Three gRNAs were also designed to target rac (Fig. 3a). After co-transformation of the Cas9/gRNA complexes and donor DNA

---

**Fig. 2.** Knock-out of ura5 in C. purpurea by CRISPR/Cas9-mediated homologous recombination (HR). (a) The knock-out strategy for the ura5 gene. (b) Diagnostic PCR using primers yUra5-F and yUra5-R. (c) Diagnostic PCR using primers hph-F and hph-R. (d) The phenotypes of C. purpurea and the ura5-deficient mutant on CD plates with or without uridine cultured for 4 weeks at 28 °C. WT, wild-type; NC, negative control (using water as the amplification template); P: plasmid containing hygromycin selectable marker; M, marker.

**Fig. 3.** Knock-out of rac in C. purpurea by CRISPR/Cas9-mediated homologous recombination (HR). (a) The knock-out strategy for the rac gene. (b) Diagnostic PCR using primers yranC-F1 and yranC-R. (c) The phenotypes of C. purpurea and the Δrac mutant on PDA plates. WT, wild-type; NC, negative control (using water as the amplification template); M, marker.
(containing the *hph* expression cassette) into *C. purpurea*, only two transformants were obtained by hygromycin screening. Fortunately, both were positive mutants, as confirmed by diagnostic PCR and Sanger sequencing (Fig. 3b). The *rac*-disruption mutants had a drastically different phenotype in axenic culture compared with the wild-type; they had a convoluted three-dimensional coralline form (without invading the agar), while the wild-type had a normal flat, two-dimensional form (Fig. 3c), as reported previously [26].

### 3.3. Using the RNP-based genome-editing system to confirm that a key enzyme participates in EAS synthesis in *C. purpurea*

The synthesis of clavines and lysergic acid derivatives starts with the formation of dimethylallyltryptophan (DMAT) from tryptophan and dimethylallylpyrophosphate (DMAPP) catalyzed by the first specific enzyme, i.e., dimethylallyltryptophan synthase (DMATS, coded by *dmaW*). Then, EasF methylates DMAT into MeDMAT. The generated MeDMAT is catalyzed by chanoclavine synthases (*easC* and *easE*) to form tetracyclic ergolene, chanoclavine-I. In the presence of EasD, the chanoclavine-I aldehyde is generated. The *easA* gene was identified to encode chanoclavine-I aldehyde oxidoreductase. Through the catalysis of EasG, agroclavine is produced. However, the P450 for the production of elymoclavine has yet been defined in the EAS pathway. Another P450 (*CloA*) is responsible for paspalic acid producing. The following process is controversial. Some researchers believe that paspalic acid spontaneously isomerizes to *n*-lysergic acid. However, some researchers believe that it is catalyzed by an unknown enzyme [27]. In ergopeptine-producing ergot fungi, *n*-lysergic acid is assembled into the corresponding D-lysergyl peptides by the action of NRPS called lysergyl peptide synthetase 1 and 2 (LPS1 and 2). Among the EAS biosynthetic cluster, *easA* is a confirmed essential gene for EAS synthesis. Using the knock-out strategy shown in Fig. 4a, the partial *easA* ORF was replaced by an integrated *hph* expression cassette. After protoplast transformation, six transformants were obtained on PDA plates with hygromycin B. These transformants were tested by PCR using the primers easA-F/R, and all six transformants produced a 3.5 kb fragment (Fig. 4b), demonstrating that the *hph* cassette replaced parts of the *easA* gene. DNA sequencing of the PCR products confirmed that the targeted partial ORF of *easA* had been knocked out. The editing efficiency of HR and CRISPR/Cas9-mediated HR was compared by introducing dDNA-*easA* (containing the *Ptrpc-*hph-Ptrpc cassette and the 3′ and 5′ flanking regions of *easA*) into *C. purpurea* protoplasts. No transforms were obtained by the direct HR approach, indicating that our CRISPR/Cas9 system is an efficient, versatile genome-editing tool for *C. purpurea*. The *easA* gene encodes a key enzyme that is thought to take part in the EAS biosynthetic pathway in *C. purpurea* (Fig. 5) [5]. Disruption of this gene may lead to biosynthetic interruption of the downstream EAS, of which ergocristine is an end product (in red in Fig. 5b). Thus, we checked whether the Δ*easA* mutants and wild-type produced ergocristine. The wild-type and *easA* mutant *C. purpurea* strains were fermented for 4 weeks, and the fermentation broths were extracted with ethyl acetate to analyze the EAS products. HPLC analysis detected no ergocristine in the fermentation extracts of the Δ*easA* mutants, while it was detected in the fermentation extracts of the wild-type strain (Figs. 4c and S9). These results indicate that inactivation of *easA* abolished EAS production in *C. purpurea*.

In summary, our CRISPR/Cas9 system based on *in vitro* assembled Cas9/gRNA RNP effectively stimulates HR in *C. purpurea*. Compared with the *in vivo* strategy in *C. purpurea*, this system has obvious advantages in terms of the process and editing efficiency (Table 1). Moreover, for those strains lacking genomic information, such as *C. purpurea* 3.1003 used here, it is difficult to establish a CRISPR/Cas9 system via an *in vivo* strategy, since neither codon-optimized Cas9 genes nor RNA polymerase III promoters can be produced without genomic information. The RNP-based method established here overcomes these difficulties via *in vitro* transcription of gRNA and purification of Cas9 protein. Because of the transient existence of the RNP complex in cells, *in vitro* assembled and delivered Cas9/gRNA-based genome editing reduces the...
risk of unnecessary gene targeting and avoids the integrated mutations that may result from gene-delivery strategies [29–31]. In conclusion, we developed a simple, efficient CRISPR/Cas9 system in C. purpurea based on gRNA in vitro transcription. Target genes were efficiently disrupted by CRISPR/Cas9-mediated HR. Based on genomic information, the candidate genes involved in EAS pathway could be deleted efficiently using our developed method. With the advantage of counter selection using 5-FOA, ura5 could be utilized as the bidirectional selection marker for recyclable genome editing. These strategies rapidly achieved simultaneous or stepwise deletion of multiple candidate genes. This work will be useful for metabolic engineering and gene regulation of C. purpurea, as well as elucidating the EAS pathway.

CRediT authorship contribution statement
Lu Yu: Conceptualization, Investigation, Writing – original draft. Meili Xio: Conceptualization, Investigation, Writing – original draft. Zhihua Zhu: Investigation. Yinmei Wang: Investigation. Zhihua Zhou: Project administration, Conceptualization, Supervision. Pingping Wang: Conceptualization, Writing – review & editing, Supervision. Gen Zhou: Conceptualization, Writing – review & editing, Supervision.

Declaration of competing interest
The authors have no interests to declare.

Acknowledgements
This work was financially supported by the National Key Research and Development Program of China (Grant No. 2019YFA0900500), the National Natural Science Foundation of China (Nos. 31921006, 31470201, and, 31741003), and the Strategic Biological Resources Service Network Plan of the Chinese Academy of Sciences (Grant No. KJF-BBP-009).

Appendix A. Supplementary data
Supplementary data to this article can be found online at https://doi.org/10.1016/j.synbio.2022.02.002.

References
[1] Silberstein SD, Shrewsbury SB, Hoekman J. Dihydroergotamine (DHE) - then and now: a narrative review. Headache 2020;60(1):40–57. https://doi.org/10.1111/head.13700.

[2] Tudyński P, Holter K, Correia T, Arntz C, Grammel N, Keller U. Evidence for an ergot alkaloid gene cluster in Claviceps purpurea. Mol Gen Genet 1999;261(1):123–41. https://doi.org/10.1007/s004380050950.

[3] Correia T, Grammel N, Ortel I, Keller U, Tudyński P. Molecular cloning and analysis of the ergopeptine assembly system in the ergot fungus Claviceps purpurea. Chem Biol 2003;10(12):1281–92. https://doi.org/10.1016/j.chembiol.2003.11.013.

[4] Haarmann T, Grammel N, Ortel I, Keller U, Tudyński P. Molecular cloning and analysis of the ergopeptine assembly system in the ergot fungus Claviceps purpurea. Chem Biol 2003;10(12):1281–92. https://doi.org/10.1016/j.chembiol.2003.11.013.

[5] Lorenz N, Olsowski J, Solk M, Tudyński P. Alkaloid cluster gene ccsA of the ergot fungus Claviceps purpurea encodes cholanclavine 1 synthase, a flavin adenine dinucleotide-containing oxidoreductase mediating the transformation of N-methyl-dimethylallyltryptophan to cholanclavine I. Appl Environ Microbiol 2010;76(6):1822–30. https://doi.org/10.1128/AEM.00737-09.

[6] Leiser J, Leiser J, Puhl M, Tudyński P, Ortel I, Keller U. Polysaccharide nosocomial adherence factor (PSNAF), a protein required for pathogenicity of the fungal pathogen Claviceps purpurea. Appl Environ Microbiol 2007;73(10):3105–10. https://doi.org/10.1128/AEM.01831-06.

[7] Leiser J, Leiser J, Puhl M, Tudyński P, Ortel I, Keller U. Polysaccharide nosocomial adherence factor (PSNAF), a protein required for pathogenicity of the fungal pathogen Claviceps purpurea. Appl Environ Microbiol 2007;73(10):3105–10. https://doi.org/10.1128/AEM.01831-06.

[8] Leiser J, Leiser J, Puhl M, Tudyński P, Ortel I, Keller U. Polysaccharide nosocomial adherence factor (PSNAF), a protein required for pathogenicity of the fungal pathogen Claviceps purpurea. Appl Environ Microbiol 2007;73(10):3105–10. https://doi.org/10.1128/AEM.01831-06.

[9] Leiser J, Leiser J, Puhl M, Tudyński P, Ortel I, Keller U. Polysaccharide nosocomial adherence factor (PSNAF), a protein required for pathogenicity of the fungal pathogen Claviceps purpurea. Appl Environ Microbiol 2007;73(10):3105–10. https://doi.org/10.1128/AEM.01831-06.

[10] Leiser J, Leiser J, Puhl M, Tudyński P, Ortel I, Keller U. Polysaccharide nosocomial adherence factor (PSNAF), a protein required for pathogenicity of the fungal pathogen Claviceps purpurea. Appl Environ Microbiol 2007;73(10):3105–10. https://doi.org/10.1128/AEM.01831-06.

[11] Leiser J, Leiser J, Puhl M, Tudyński P, Ortel I, Keller U. Polysaccharide nosocomial adherence factor (PSNAF), a protein required for pathogenicity of the fungal pathogen Claviceps purpurea. Appl Environ Microbiol 2007;73(10):3105–10. https://doi.org/10.1128/AEM.01831-06.

[12] Leiser J, Leiser J, Puhl M, Tudyński P, Ortel I, Keller U. Polysaccharide nosocomial adherence factor (PSNAF), a protein required for pathogenicity of the fungal pathogen Claviceps purpurea. Appl Environ Microbiol 2007;73(10):3105–10. https://doi.org/10.1128/AEM.01831-06.

[13] Leiser J, Leiser J, Puhl M, Tudyński P, Ortel I, Keller U. Polysaccharide nosocomial adherence factor (PSNAF), a protein required for pathogenicity of the fungal pathogen Claviceps purpurea. Appl Environ Microbiol 2007;73(10):3105–10. https://doi.org/10.1128/AEM.01831-06.

[14] Leiser J, Leiser J, Puhl M, Tudyński P, Ortel I, Keller U. Polysaccharide nosocomial adherence factor (PSNAF), a protein required for pathogenicity of the fungal pathogen Claviceps purpurea. Appl Environ Microbiol 2007;73(10):3105–10. https://doi.org/10.1128/AEM.01831-06.
[28] Liu R, Chen L, Jiang Y, Zhou Z, Zou G. Efficient genome editing in filamentous fungus Trichoderma reesei using the CRISPR/Cas9 system. Cell Discov 2015;1:15007. https://doi.org/10.1038/celldisc.2015.7.

[29] Lin S, Staahl BT, Alla RK, Doudna JA. Enhanced homology-directed human genome engineering by controlled timing of CRISPR/Cas9 delivery. Elife 2014;3:e04766. https://doi.org/10.7554/eLife.04766.

[30] Ramakrishna S, Kwaku Dad AB, Beloor J, Gopalappa R, Lee SK, Kim H. Gene disruption by cell-penetrating peptide-mediated delivery of Cas9 protein and guide RNA. Genome Res 2014;24(6):1020–7. https://doi.org/10.1101/gr.171264.113.

[31] Zuris JA, Thompson DB, Shu Y, et al. Cationic lipid-mediated delivery of proteins enables efficient protein-based genome editing in vitro and in vivo. Nat Biotechnol 2015;33(1):73–80. https://doi.org/10.1038/nbt.3081.